Benutzer: Gast  Login
Titel:

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).

Dokumenttyp:
Journal Article; Article
Autor(en):
Wagner, U; du Bois, A; Pfisterer, J; Huober, J; Loibl, S; Luck, HJ; Sehouli, J; Gropp, M; Stahle, A; Schmalfeldt, B; Meier, W; Jackisch, C
Abstract:
BACKGROUND: Tamoxifen and gefitinib (IRESSA) combination therapy was studied in patients with ovarian cancer refractory or resistant to platinum- and taxane-based therapy. PATIENTS AND METHODS: In this phase II study, 56 patients with epithelial ovarian carcinoma or cancer of the fallopian tube or peritoneum received oral tamoxifen 40 mg/day and gefitinib 500 mg/day until progression or unacceptable toxicity. RESULTS: Seventeen patients (mean age: 59.6 years) had previously received first-line p...     »
Zeitschriftentitel:
Gynecol Oncol
Jahr:
2007
Band / Volume:
105
Heft / Issue:
1
Seitenangaben Beitrag:
132-7
Sprache:
eng
Volltext / DOI:
doi:10.1016/j.ygyno.2006.10.053
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/17161453
Print-ISSN:
0090-8258
TUM Einrichtung:
Frauenklinik und Poliklinik
 BibTeX